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Abstract 
 
The relationship between immune status and employment outcomes in HIV-infected patients on long-
term antiretroviral therapy (ART) in sub-Saharan Africa and their HIV-affected households is not well 
understood. We assessed the relationship between CD4+ T-cell counts of ART-treated adults at public-
sector clinics in Lusaka, Zambia (median treatment duration 973 days) and labour force participation in 
the HIV-affected households using clinical and survey data. In multivariable models, patients with a 
CD4+ count >350 cells/µl were 22 percentage points more likely to be engaged in labour (95% CI: 0.02, 
0.42) and worked approximately 6 more days per month compared to patients with a CD4+ count <350 
cells/µl.  A similar relationship between patient CD4+ count and labour participation was observed for 
other adult family members in the HIV-affected household, but it was not statistically significant.  These 
findings suggest interventions that promote and maintain robust immune recovery on ART may confer 
economic benefits. 
 
Keywords: HIV, Africa, CD4 count, employment, household
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Introduction 
In addition to a profound toll in morbidity and mortality, the HIV epidemic in sub-Saharan Africa has had 
severe economic consequences for HIV-infected individuals, their families, and national economies (1-3). 
Progressive debilitation from untreated HIV disease reduces the capacity for labour force participation 
and economic productivity among working-age adults, which negatively impacts the household through 
reduced income and the burden of caring for chronically ill family members (2, 4-6). However, with the 
rapid scale up of access to antiretroviral therapy (ART) in sub-Saharan Africa over the past decade, 
patients are now surviving far longer on treatment. Prior studies found increased labour force 
participation, income, and other economic benefits among HIV-infected individuals starting ART, but the 
relationship between the immune status of patients on long-term ART and individual and household 
economic outcomes are not well described (7-11). 
 
A recent analysis of CD4+ T-cell counts and employment outcomes in 168 HIV-infected Ugandan adults 
(37% on ART) found that patients with a CD4+ T-cell count over 350 cells/µl worked an average of 6 
more days per month than patients with a CD4+ count under 200 cells/µl, and those with a CD4+ count 
over 500 cells/µl worked 44% more hours per week compared to those under 200 cells/µl (11). A second 
study in 505 HIV-infected Ugandan adults not yet on ART found lower labour force participation among 
those with a CD4+ count less than 200 cells/µl compared to patients above that value (9). However, after 
one year of ART those who started below 200 cells/µl had reached parity with those starting at a higher 
CD4+ count, and both groups maintained similar trajectories in labour participation going forward. 
 
To date, most studies have assessed the relationship between CD4+ T-cell count and patient employment 
outcomes prior to or shortly after ART initiation, but there has not been an adequate assessment of how 
the immune status of patients on long-term ART impacts both patient labour participation and other adult 
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family members in the HIV-affected household. Using clinical and economic data collected from HIV-
infected patients on long-term ART and their households, we assessed whether patient CD4+ T-cell 
counts were associated with aspects of labour force participation in HIV-affected households in Lusaka, 
Zambia. We hypothesised that a more robust immune recovery on ART would result in increased labour 
force participation by the patient, and a reduced care burden would permit other family members to seek 
employment. 
 
Methods 
Participant recruitment 
We randomly sampled 179 patients receiving ART at four clinics located in the Bauleni, Chipata, 
Matero, and Chilenje neighbourhoods of Lusaka. All patients were 18 years of age or older and 
constituted 7% of the active ART patient population at the clinics. The collection of clinical and 
economic data for this analysis was performed as part of an impact assessment for a World Food 
Program-Zambia (WFP) program to provide food baskets to HIV-affected individuals and households in 
Lusaka, Zambia (12). The patients in this analysis comprise the control cohort at clinics not involved in 
the food distribution program.  
 
Data collection 
All participants completed a household survey questionnaire in August 2009. The questionnaire was 
refined through pre-testing at the Bauleni and Chawama clinics. The survey captured information on 
household demographics, employment outcomes, household expenditures, income sources, dwelling 
conditions, and productive and durable assets owned. Clinical data on duration of ART treatment and 
CD4+ T-cell counts were obtained from the SmartCare electronic database of the Zambian national HIV 
treatment program. The window period for CD4+ T-cell counts was pre-specified as the value closest to 
August 1, 2009 within 60 days before or after this date; an approach used by previous similar studies (7, 
13). Only 112 of the 179 (63%) patients had CD4+ cell count information within the window period and 
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formed the analytical sample. 
 
Key variables 
The survey had a module to capture information on formal or informal income generating work 
performed by household members over age 18. Examples included farm work, owning a business of any 
size, and salaried work. Three variables were used to measure employment outcomes. Two were 
continuous variables; number of hours worked in the previous week and the number of days worked 
during the previous month. One variable was binary and it measured participation in any income 
generating work at the time of the survey (coded as 1-yes and 0-no).  
 
Statistical analyses 
The key independent variable in this study is CD4+ T-cell count. We used a binary classification of 
CD4≥350 cells/µl and CD4<350, which was based on the 2010 and 2013 WHO recommendations for 
ART treatment initiation (14, 15), clinical trials and observational studies showing worse health 
outcomes among patients with a CD4+ T-cell count <350 cells/µl at ART initiation (16-18), and to 
permit comparisons with prior studies of economic outcomes (11).  
 
Three types of regressions were performed. Ordinary least squares regressions were used to determine 
the association between the CD4+ T-cell count of ART-treated adult patients and the continuous 
outcome variables (number of hours worked in previous week and number of days worked in previous 
month). A probit model was used to examine the association between the CD4+ T-cell count of ART-
treated adult patients and the binary outcome variable (i.e., whether the patient participates in any 
income generating work). A probit regression was utilised to express the effect size in percentage points 
or marginal effects, which provides a more straightforward interpretation of labour force participation 
rates, as opposed to odds ratios.  All regression models were adjusted for age, sex, an interaction 
between age and sex, duration of ART and education attainment (i.e. some formal education versus 
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none). We utilised the same models to assess the relationship between the ART-patient’s CD4+ T-cell 
count and employment outcomes among non-patient adult members in the HIV-affected household. 
 
The regression models were also used to obtain the predicted values of the employment outcomes. Non-
parametric regression (kernel-weighted local polynomial regression with a zero degree polynomial) 
examined the association between the duration of ART and the predicted values of the three employment 
outcomes by comparing individuals with CD4≥350 and CD4<350. These analyses assessed whether the 
duration of ART mediates the influence of CD4+ T-cell count on employment.  All statistical analyses 
were performed using Stata/SE 13.1 (StataCorp, College Station, Texas, USA). 
 
Ethical approval 
Ethical approval was obtained from the University of Zambia Research Ethics Committee and the 
Ministry of Health of the Republic of Zambia. All participants provided written informed consent. 
 
 
Results 
The analytical sample is composed of 311 individuals, comprising 112 adult patients receiving ART and 
199 non-patient adults. Table 1 describes the socio-demographic characteristics of the cohort. About 
70% of the patients were female compared to nearly 47% of the non-patient adults.  On average, patients 
were older than non-patients by 10 years. The marriage and educational attainment rates of the patients 
and non-patients are similar. Among the patients receiving ART, the median CD4+ T-cell count was 
349 cells/µl (IQR: 245– 481) and the median duration of ART was 973 days (IQR: 523-1434). 
 
Descriptive statistics of employment outcomes  
Table 2 shows the means of each employment outcome for patients and non-patients. About 47% of 
patients with CD4≥350 participated in income generating work compared to around 32% of patients with 
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CD4<350.  The mean number of days worked in the past months were higher for patients with CD4≥350 
(16.4 days) compared to those with CD4<350 (12.0 days).  For patients with CD4≥350 and CD4<350, the 
mean number of hours worked in the past week were 18.0 and 13.0 hours respectively.    
 
In households of ART-treated patients with CD4≥350 (high) and CD4<350 (low), the mean number of 
days worked in the previous month by non-patient adults were 12.2 days and 10.8 days respectively, and 
the mean hours worked in the previous week were 10.2 and 12.2 hours respectively. Participation in work 
rates for non-patient adults were lower in households of patients with CD4<350 (30%) than in households 
of patients with CD4≥350 (38%). 
 
Association between CD4+ T-cell count and employment outcomes of HIV patients and adult family 
members 
The adjusted regression estimates in Table 3 show that ART-treated patients with CD4≥350 were 22 
percentage points more likely to be in the labour force than those with CD4<350  (95% confidence 
interval [CI]: 0.02, 0.42, p<0.05). Patients with CD4≥350 worked 5.97 more days in the previous month 
than those with CD4<350 (CI: 0.47, 11.47, p<0.05). On average, patients with CD4≥350 worked 9.06 
more hours in the past week than those with CD4<350 (CI: -0.02, 18.14, p=0.05).  
 
Table 4 presents the results for the non-patient adult members living in the households with ART-treated 
adult patients. The results show that living with a patient with CD4≥350 was associated with a greater 
likelihood of labour force participation, nearly one more day worked in the previous month, but a two 
hour decrease in hours worked in the previous week. However these effects were not statistically 
significant. In results not reported here, we estimated additional models for both patients and non-patient 
adults which included dummy variables for the residential community for the households, to control for 
any unobserved location specific confounders. However, the results for both patients and non-patients did 
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not change.  
 
After estimating the association between CD4≥350 and employment outcomes, we obtained the 
predicted values of the employment outcomes for the HIV-infected patients receiving ART. Non-
parametric regressions (kernel-weighted local polynomial regression with zero degree polynomials) 
were used to examine whether the association between a high CD4+ T-cell count and predicted 
employment outcomes varies by the length of time on ART. Comparing individuals with high CD4+ T-
cell count (≥350) to those with low CD4+ count (<350) the non-parametric regressions estimated the 
association between predicted values of the employment outcomes and duration of ART (Figure 1). At 
all points along the distribution of days receiving ART, patients with  CD4≥350 consistently had higher 
probabilities (above 50%) of labour force participation, more days and hours worked than those with 
CD4<350. The gap between patients with CD4≥350 and those with CD4<350 is largely similar at both 
the low and high end of the distribution of ART duration, suggesting time-on-treatment was not a major 
confounder. 
 
Supplementary Table 1 presents the results for sensitivity analyses assessing the effects of a change in 
the CD4+ T-cell count threshold to 500 cells/µl, and the addition of the patient’s medication possession 
ratio (MPR) at the time of the survey to the multivariable models. The MPR is a measure of adherence 
based on pharmacy refill data which is shown to correlate with the risk of virologic failure (19, 20). ART-
treated patients with CD4≥500 were 26 percentage points more likely to be in the labour force than those 
with CD4<500 (CI: 0.02, 0.51, p<0.05). Patients with CD4≥500 worked 5.66 more days in the previous 
month than those with CD4<500 (CI: 0.47, 11.47, p=0.1). On average, ART-treated patients with 
CD4≥500 worked 13.23 more hours in the past week than those with CD4<500 (CI: 2.45, 24.02, p<0.05). 
The results also show that non-patient adults living with a patient with CD4≥500 were also 26 percentage 
points more likely to be in the labour force than those with living with a patient with CD4<500 (CI: 0.06, 
0.46, p<0.05).  They also worked 4.7 more days in the previous month, and about 0.62 more hours in the 
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previous week. However these effects were not statistically significant. When MPR was included in the 
models assessing a CD4>350 versus CD4<350 the results were similar to those from the primary analysis 
in Tables 3 and 4. 
 
Discussion 
In this analysis of HIV-infected, working-age adults on long-term ART in urban Lusaka, Zambia, we 
found that a higher CD4+ T-cell count was associated with improved employment outcomes. After 
accounting for the duration of ART treatment and other factors, we found that ART-treated patients with 
CD4+ T-cell counts above 350 cells/µl were 22 percentage points more likely to be in the labour force, 
and they worked approximately 6 more days per month, and 9 more hours per week, than patients with a 
CD4+ T-cell count below this threshold. A sensitivity analyses showed a CD4+ count over 500 cells/µl 
was also associated with similar work participation rates for the patients. To our knowledge, this is the 
first study to assess the effect of CD4+ T-cell counts on labour force participation among patients on 
long-term ART. Our findings are similar to a recent study by Thirumurthy et al.(2013) of CD4+ T-cell 
counts and labour force participation among HIV-infected adults in Uganda, the majority of whom (63%) 
had not yet started ART (11). In that analysis, HIV patients with a CD4+ T-cell count over 350 cells/µl 
were found to work 6 more days per month than patients with a CD4+ count under 200 cells/µl, while 
those with a CD4+ count over 500 cells/µl worked 44% more hours per week compared to those with less 
than 200 cells/µl. 
 
In contrast to prior studies, we also assessed the relationship between the CD4+ T-cell count of ART-
treated patients and the employment outcomes of non-patient adults in the same household. We 
hypothesised that a more robust immune recovery for individuals on ART would result in a reduced care 
burden and provide greater opportunity for other family members to seek employment. Among non-
patient adults in the households of ART-treated patients, we observed a similar directionality in the 
relationship between the HIV-infected family member’s CD4+ T-cell count and labour force 
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participation, but the results were not statistically significant. However, a sensitivity analysis showed that 
living with a patient with a CD4+ T-cell count over 500 cells/µl, rather than over 350 cells/µl,  was 
associated with higher and statistically significant labour force participation for non-patient adults in the 
household. This finding may indicate that more opportunities to work become available as the HIV-
infected family member’s immune status improves.  
 
We found that patients with a CD4+ T-cell count ≥350 cells/µl had consistently greater labour force 
participation than those with <350 at differing levels of time spent on ART, suggesting our findings were 
not primarily due to a longer treatment duration. This area deserves further investigation, as plasma HIV-
1 RNA measurements were not a routine component of care in Zambia at the time of the study and we 
were unable to ascertain whether poor CD4+ T-cell recovery despite a relatively long duration of ART 
was due to immunologic non-response or inadequate viral suppression. Poor immune recovery and 
persistent immune activation despite virologic suppression are associated with functional impairment and 
frailty in HIV-infected adults, though the directionality of this relationship is unclear (21, 22). Future 
studies should assess whether measurements of virologic suppression and functional capacity after ART 
initiation (e.g., grip strength or lean mass recovery) can predict patient and household employment 
outcomes better than CD4+T-cell count (23). 
 
Current guidelines for the initiation of ART in Zambia are a CD4+ T-cell count <350 cells/µl or Stage 3 
or 4 HIV disease. However, most HIV-infected individuals present for care in Zambia with CD4+ counts 
below this level, and up to a third have malnutrition and/or advanced immunosuppression at ART 
initiation (24, 25). Our finding that ART-treated patients with CD4+ T-cell counts above the Zambian 
ART-initiation threshold had better employment outcomes suggest that earlier diagnosis and ART 
initiation may have important individual and household economic effects. Prior studies of untreated HIV 
infection found debilitation and reduced labour force participation accelerated in the last 2 years before an 
employee stopped working due to advanced disease or AIDS (2, 4). At the household level, the presence 
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of a family member with advanced HIV reduced yearly income by 30-35% in one study (6), and resulted 
in markedly lower agricultural output in farming families (26, 27). At the community level, a high 
prevalence of untreated HIV disease compounds famine severity (28), while the illness or death of a 
primary earner increases high-risk sexual behaviours among remaining family members (29, 30) and 
increases the number of abandoned and orphaned children (31). While we cannot conclude from our study 
that initiating ART at a CD4+ T-cell count greater than 350 cells/µl (the current guidelines in Zambia) 
would have beneficial economic effects, our results do suggest that the treatment of HIV prior to 
advanced immunosuppression confers an economic benefit. 
 
Poverty and food insecurity are associated with reduced clinic attendance, and our results may reflect an 
effect of a higher pre-treatment economic and employment position on the ability of patients to attend 
clinic visits, and consequently maintain ART adherence, achieve viral suppression, and promote 
immunologic recovery (32, 33). Our sensitivity analysis adjusted for MPR rates at the time of the 
assessment, a measure of adherence shown to correlate with the risk of virologic failure in prior studies 
(19, 20).  The results were very similar to the results of our main models. However, we could not assess 
prior MPR values or ascertain the presence of antiretroviral resistance mutations contributing to persistent 
viremia despite a high MPR.  
 
Our study had several limitations. The cross-sectional design precluded the assessment of causal 
relationships between CD4+ T-cell count and labour force participation. We were also unable to assess 
the relationships between pre-treatment CD4+ T-cell count, the rate of CD4+ recovery on ART, and 
economic outcomes. Furthermore, the association between current CD4+ T-cell count and labour force 
participation may be confounded, in part, by a patient’s economic status prior to ART initiation. Patients 
with greater resources may be more likely to receive HIV testing, seek earlier medical care, and have the 
resources to attend clinic appointments, maintain adherence, and purchase sufficient food to recover from 
any HIV-related nutritional deficits. While CD4+ T-cell count is a reliable measure of immune recovery, 
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future studies should also include measurements of functional status and frailty, particularly in those 
patients who initiated ART with advanced disease. Additionally, our survey data did not capture other 
potential confounders of immune recovery such as robust social networks and mental health, which could 
influence disease severity at treatment initiation, continuity of care, and adherence (34, 35). Among non-
patient adults living in the HIV-affected household, we did not assess HIV status due to concerns 
regarding privacy, response bias, and the potential for undiagnosed HIV infections in our setting, and we 
were unable to assess the functional capacity of the non-patients.  It is also possible that there is a 
bidirectional association between employment and immune status, a confounding effect that is better 
assessed with longitudinal data.  Lastly, our study cohort was primarily female and drawn from an urban 
population in Zambia, and the results may not be representative of men, rural populations, or other 
countries in the region.  
 
In conclusion, we observed a strong association between a CD4+ T-cell count above 350 cells/µl and the 
labour force participation of patients on long-term ART in Zambia, and a similar directional relationship 
for adults living in the HIV-affected household that did not reach statistical significance. These findings 
have implications for testing and linkage to care of HIV-infected persons in sub-Saharan Africa. 
Treatment initiation at higher CD4+ T-cell counts likely has economic benefits at the household level. 
Future longitudinal studies are warranted to understand relationships between HIV disease severity and 
economic status from HIV diagnosis through ART initiation and long-term treatment, with more 
comprehensive assessments of socioeconomic outcomes such as asset wealth, household food security, 
and child health and education.   
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Table 1 Description of the participant cohort 
Characteristic Adult patients on ART (n=112) Non-patient adults in the same household 
(n=199) 
   
Female, % 70.54 46.97 
No education, % 15.18 15.08 
Married, % 45.54 45.73 
Age, mean 40.92 30.59 
CD4 count, cell/mm3   
≥350, % 49% NA 
Mean (SD) 373 (190)  
Median (IQR) 349 (245-481)  
Duration of ART, days   
Mean (SD) 978 (505) NA 
Median (IQR) 973 (523-1434)  
Notes: Abbreviations. IQR: interquartile range. ART: antiretroviral therapy 
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Table 2: Comparison of household demographics and employment outcomes according to HIV-
infected patient CD4+ T-cell counts 
                                    Households 
Variable CD4≥350 
n=55 
CD4<350 
n=57 
p-value 
Female, %    
Patients 84 58 <0.001 
Adults living in same household 45 49 0.54 
No education, %    
Patients 9 18 0.19 
Adults living in same household 11 21 0.05 
Married, %    
Patients 42 49 0.44 
Adults living in same household 38 56 0.05 
Age, mean years    
Patients 40.9 41.0 0.94 
Adults living in same household 31.5 29.4 0.24 
Participated in income generating work, %    
Patients 47.3 31.6 0.09 
Adults living in same household 38.4 29.9 0.21 
Days worked in previous month (mean)    
Patients 16.4 12.0 0.09 
Adults living in same household 12.2 10.8 0.59 
Hours worked in previous week (mean)    
Patients 18.0 13.0 0.26 
Adults living in same household 10.2 12.2 0.51 
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Table 3 Association between CD4 count and the employment outcomes of patients 
 (1) (2) (3) 
Outcome Labour force participation  
ME 
Days worked in previous 
month 
Hours worked in previous week 
CD4 ≥350 
cells/µl 
0.22** [0.02,0.42] 5.97** [0.47,11.47] 9.06* [-0.02,18.14] 
Age, per year -0.012 [-0.03,0.01] -0.67** [-1.24,-0.10] -0.75 [-1.71,0.22] 
Female -0.71** [-1.34,-0.08] -38.7*** [-67.86,-9.46] -56.8** [-105.98,-7.61] 
Female x age 0.02 [-0.01,0.04] 0.82** [0.15,1.49] 0.95* [-0.17,2.08] 
Days on ART 2.44E-06 [-0.0002,0.0002] 0.001 [-0.004,0.01] 0.003 [-0.01,0.01] 
No education -0.19 [-0.42,0.04] -4.33 [-11.26,2.60] -3.59 [-15.17,8.00] 
       
Observations 112  106  112  
Notes: ME denotes that marginal effects are reported in column 1 (probit regression); patients on ART with CD4>350 were 22 
percentage points more likely to be engaged in economic activity. Regression coefficient shown in columns 2 and 3 represent 
absolute days and hours, respectively; 95% confidence intervals are in parentheses. * p < 0.10, ** p < 0.05, *** p < 0.01. No 
education refers to whether individual was never formally educated. Female x age is an interaction of female and age. 
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Table 4 Association between HIV-patient CD4 count and the employment outcomes of non-patient 
adults in the same household 
 
Outcome 
(1) 
Labour force participation 
(2) 
Days worked in previous 
month 
(3) 
Hours worked in previous 
week 
CD4 ≥350 
cells/µl in HIV-
infected family 
member 
0.04 [-0.12,0.20] 0.91 [-5.00,6.81] -2.00 [-8.96,4.97] 
Age 0.01** [0.00,0.02] 0.18 [-0.12,0.49] 0.43** [0.07,0.79] 
Female -0.23 [-0.58,0.13] 0.75 [-13.09,14.59] 0.33 [-16.04,16.69] 
Female x age -0.001 [-0.01,0.01] -0.15 [-0.57,0.27] -0.23 [-0.73,0.27] 
Days on ART -0.00003 [-0.0002,0.0001] -0.002 [-0.01,0.003] -0.01 [-0.01,0.002] 
No education -0.17** [-0.33,-0.01] -6.14* [-13.28,0.99] -1.60 [-9.86,6.65] 
       
Observations 185  171  185  
Notes: Marginal effects in column 1 (probit regression). Regression coefficients are shown in columns 2 and 3; 95% confidence 
intervals are in parentheses. * p < 0.10, ** p < 0.05, *** p < 0.01. No education refers to whether individual was never formally 
educated. Female x age is an interaction of female and age. 
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Supplementary Table 1: Sensitivity analyses for the relationship CD4 count and the employment 
outcomes of patients and non-patient adults in the same household 
 (1) (2) (3) 
Patients Labour force participation  
ME 
Days worked in previous month Hours worked in previous 
week 
CD4 ≥500 cells/µl 0.26** [0.02,0.51] 5.66 [-1.11,12.43] 13.23** [2.45,24.02] 
CD4 ≥350 cells/µl 
(adjusted for MPR) 
0.22** 0.010.42] 5.79** [0.24,11.34] 8.53* [-0.59,17.64] 
Observations 112  106  112  
Non-patient adults       
CD4≥500 0.26** [0.06,0.46] 
 
4.70 [-2.18,11.57] 0.62 [-7.50,8.74] 
CD4≥350  
(adjusted for MPR) 
0.04 [-0.12,0.20] 0.77 [-5.17,6.71] -2.33 -9.29,4.64] 
       
Observations 185  171  185  
Notes: All models adjusted for age, sex, duration of ART and education. ME denotes that marginal effects are reported in column 
1 (probit regression). Regression coefficients are shown in columns 2 and 3; 95% confidence intervals are in parentheses. * p < 
0.10, ** p < 0.05, *** p < 0.01. The first sensitivity analysis compares the outcomes among ART-treated patients with a CD4+ 
T-cell count over 500 cells/µl versus those below that leve1. The second analysis adjusts for the medication possession ratio (a 
measurement of adherence based on pharmacy refill data). No education refers to whether individual was never formally 
educated. Female x age is an interaction of female and age. 
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Figure 1 Role of the duration of ART on patient employment 
 
Notes:   Nonparametric regression estimates of the association between duration of ART and predicted values of 
employment outcomes for patients. Results from kernel-weighted local polynomial regressions (zero degree 
polynomial) with width of 200 days around each point and estimated locally at 50 points. Regressions compare 
patients high CD4 count (CD4≥350=1) and those with low CD4 count (CD4<350=1).  Abbreviation: Prob; 
probability. 
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